rajEndiran

An example of crystal storing histiocytosis; the patient needs to be evaluated for a plasma cell disorder or other lambda-restricted B cell neoplasm. Arnold CA, et al. Am J Surg Pathol. 2018 Oct;42(10):1317-1324. PMID: 29878935.

Challenges of staging appendiceal mucinous neoplasms Mucin outside the appendix in a LAMN case, is it pT4 or not? -Acellular mucin without inflammatory reaction, mesothelial hyperplasia, or neovascularization is presumed to be a result of carryover during handling or gross examination, and should not be designated as pT4a (Pic A) - Organizing acellular mucin with neovascularization on the serosal surface is categorized as pT4a (Pic B) Umetsu et al doi.org/10.1016/j.hump…

Membranous nephropathy is no longer just “primary vs secondary” disease — it is now an ANTIGEN-SPECIFIC podocytopathy. 🔬 Newer antigens are redefining diagnosis & prognosis: ▪️ NELL1 → malignancy/drug-associated MN ▪️ EXT1/EXT2 & NCAM1 → lupus/autoimmune MN ▪️ SEMA3B → pediatric MN ▪️ FAT1 → post-HSCT MN ▪️ CNTN1 → neuropathy-associated MN ▪️ PCDH7 → indolent MN phenotype ⚡ Emerging concept: Dual-antigen MN (NELL1+PLA2R, NCAM1+EXT1/2 etc.) suggesting complex autoimmune evolution. 🧪 Mass spectrometry-based antigen mapping is becoming the future gold standard for PLA2R-negative MN. #GSR #BuddingNephros #MembranousNephropathy #RenalPathology #NephTwitter #MedTwitter

Amyloidosis

🔬 Molecular Pathology of Adipocytic Tumors — High-Yield Map Morphology 🧫 + genetics 🧬 + behavior ⚠️ in one glance. Lipoma (HMGA2) → ALT/WDL (MDM2/CDK4) → DDL (JUN). 🎯 Rapid revision for FRCPath | NEET SS #Pathology #MolecularPathology #Liposarcoma #Lipoma #FRCPath #NEETSS

A one-stop revision sheet covering all major cytology systems with crucial numeric cut-offs 🔢, adequacy thresholds ✅, key cellular requirements 🧫, and diagnostic exceptions⚠️ Perfect for last-minute revision ⏱️and quick glance recall 👀 #Pathology #Cytology #HighYield #NEETSS

Flower cells seen in blood smear. Which disease is this?

1/2 HEMATOLOGY feels impossibly broad… until you realize most problems start in just 4 compartments: 🩸 red cells ⚪ white cells 🟣 platelets 💧 plasma

#TooCloseToDiagnose??? #PathQuiz 🔬☀️ #DermPath A) Bowen disease B) Actinic keratosis C) Lichen planus-like keratosis D) Seborrheic keratosis

Interesting case of the week. 63-year-old woman with a “breast cyst”. What do you think? #breastpath #dermpath #surgpath #pathology

#slidearchiveseries vasculogenic mesenchymal tumor #gupath #pathtwitter #pathoutpic 🔬 neoplastic vessels in smooth muscle stroma 1️⃣ post-ChT resections of primary mediastinal GCT with YST components 2️⃣ risk of sarcoma 3️⃣ risk of leukemia/myelodysplasia pubmed.ncbi.nlm.nih.gov/33136584/

Mesothelial cell : tips and tricks for cytology of effusions. #cytopath #PathBoards

Hey! A short illustration on the approach of #lymphoma! Hope it may help! #pathology #pathresident #pathognosis

hematomorph.com💞💞

✅ NIFTP 🎯🦋 • Must be totally encapsulated or completely demarcated from parenchyma. • Shows exclusive follicular growth with less than 1% true papillae. • RAS mutations are the main drivers, occurring in 52% of cases. • This reclassification avoids overtreating extremely indolent tumors.

Histology of Breast at Various Ages Dr. Hoda. Histology Bootcamp-Breast #USCAP25 #PathX #pathology

Sarcomas that metastasize to lymph nodes should “SCARE” you! These are: S Synovial sarcoma C Clear cell sarcoma A Angiosarcoma R Rhabdomyosarcoma E Epithelioid sarcoma #BST #sarcoma #Dermpath #boards #pathtwitter #pathx #mnemonic

HYPERCHOMIC (DENSE) RBCs Loss of central pallor is not always a spherocyte. Individual cell density does not always translate to ↑ MCHC. MCHC rises only when dense cells are numerous enough. (Corrected schematic)

We recently discussed t(11;14), t(4;14), and t(14;16). Today—let’s simplify what matters most at the bedside: 👉 t(11;14) = “Leaky myeloma” 💧 👉 t(14;16) = “Sticky myeloma” 🧲 Yes… leaky vs sticky. 💧 t(11;14) — LEAKY    •   CD56 negative → no adhesion    •   Cells don’t stay in marrow → spill into blood    •   PB involvement, EMD more common 🧠 Think: No glue → no home → they wander 🎯 Biology: BCL-2 dependent → Target the protein (venetoclax) 🧲 t(14;16) — STICKY    •   MAF → adhesion molecules + IL-6 signaling    •   Early disease: locked in marrow niche    •   Protected, hidden, therapy-resistant 🧠 Think: Glued in place… safe for now 💥 Then evolution happens: → Lose niche dependence → Break out → aggressive EMD 🎯 The big difference:    •   t(11;14) → escapes early    •   t(14;16) → escapes late… and worse ⚡ Clinical translation:    •   Leaky → target the vulnerability (BCL-2)    •   Sticky → disrupt the environment + multi-agent therapy 🧠 If you remember one thing: 💧 If it leaks → shut the valve 🧲 If it sticks → break the niche ✍️ Dr Fun + G #myeloma #hemetwitter

A new Clinical Practice article summarizes the pathogenesis, diagnosis, and management of Barrett’s esophagus, a reflux-related condition with increased adenocarcinoma risk, highlighting endoscopic diagnosis, surveillance, and early curative therapy. Read “Barrett’s Esophagus” by Rebecca C. Fitzgerald, MD (@RFitzgerald_lab), from the University of Cambridge (@cambridge_uni): nejm.org/doi/full/10.10… #Oncology